Sumary of FB-EVAR is safe and effective for treatment of aortic aneurysms, study shows:
- The study, “Midterm Outcomes of a Prospective, Nonrandomized Study to Evaluate Endovascular Repair of Complex Aortic Aneurysms Using Fenestrated-Branched Endografts,” led by senior author Gustavo S. Oderich, MD, was published in the September 2021 Annals of Surgery and presented at the American Surgical Association meeting.
- The study focused on treatment of complex aortic aneurysms, including pararenal and thoracoabdominal aortic aneurysms, which affect the aorta and the branches to the kidneys and intestines.
- The device is manufactured to fit the anatomy of the patient with specialized fabric tube “windows” (fenestrations) or side arms (“branches”) supported by a structure of stainless steel or nickel-titanium alloy wires.
- The researchers reported that endovascular repair using fenestrated and branched endografts was associated with a 1% risk of mortality at 30 days, which compares to a mortality of 21% in a recent study of over 14,000 patients treated by open surgical repair in the United States.
- When we began the study, we had no idea the rate of mortality would be so much lower than the historical results of open surgical repair.
- ” Gustavo S. Oderich, MD, Senior Author Related StoriesThe study, which included 430 patients with an average age of 74, also showed better outcomes regarding major adverse events, including paralysis and paraplegia caused by spinal cord injury.
- Spinal cord injury affected 6% of patients enrolled in the FB-EVAR study, which is similar to contemporary open surgical studies in which the rate of spinal cord injuries reported was 5% to 10%.